Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp trimmed its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 1.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 199,981 shares of the company's stock after selling 2,308 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.64% of Medpace worth $66,440,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. R Squared Ltd bought a new position in shares of Medpace during the 4th quarter valued at about $30,000. Stone House Investment Management LLC purchased a new stake in shares of Medpace in the third quarter worth about $33,000. Ashton Thomas Securities LLC bought a new position in Medpace during the third quarter valued at approximately $37,000. Capital Performance Advisors LLP purchased a new position in Medpace during the 3rd quarter valued at approximately $46,000. Finally, True Wealth Design LLC increased its stake in Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company's stock worth $56,000 after acquiring an additional 168 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

Separately, Robert W. Baird increased their target price on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $381.44.

Remove Ads

Medpace Stock Up 1.1 %

Shares of NASDAQ MEDP traded up $3.70 during midday trading on Friday, reaching $329.43. 168,128 shares of the company's stock traded hands, compared to its average volume of 297,285. The company has a market cap of $10.04 billion, a price-to-earnings ratio of 26.09, a P/E/G ratio of 3.81 and a beta of 1.36. The stock's 50 day simple moving average is $341.27 and its 200-day simple moving average is $344.03. Medpace Holdings, Inc. has a one year low of $302.01 and a one year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.